Document 0512
 DOCN  M9550512
 TI    High versus ultra-high purity factor VIII concentrate therapy:
       prospective evaluation of immunological and clinical parameters in HIV
       seronegative and seropositive hemophiliacs.
 DT    9505
 AU    Varon D; Schulman S; Dardik R; Barzilai A; Bashari D; Martinowitz U;
       National Hemophilia Centre, Chaim Sheba Medical Centre,; Tel-Hashomer,
       Israel.
 SO    Thromb Haemost. 1994 Sep;72(3):359-62. Unique Identifier : AIDSLINE
       MED/95159067
 AB    This study aimed at evaluation of the immunological status and the
       clinical course of both HIV seronegative and seropositive hemophiliacs
       treated with either an ultra-pure factor VIII product (UP-F VIII), or a
       high-purity F VIII (HP-F VIII) concentrate. Eighteen HIV seronegative
       patients were divided into two groups of therapy and their immune status
       was followed for 2 years. During the second year of the study 8 patients
       of the HP-F VIII and 6 from the UP-F VIII therapy groups were switched
       to the alternative F VIII concentrates. Eighteen asymptomatic HIV
       seropositive patients were also divided into therapy groups and their
       immune status and any development of HIV-related symptoms were followed
       for 4 years. Evaluation of the HIV seronegative patients during the
       first year did not reveal any differences between the groups in the CD4
       or CD8 cell counts, in natural killer cell (NK) activity, or in the
       mitogenic responses of T lymphocytes to Phytohemagglutinin (PHA), and of
       B lymphocytes to Pokeweed mitogen (PWM). The switch of 8 patients from
       the HP-F VIII and 6 from the UP-F VIII groups to the alternative
       concentrate did not yield any changes in their immune profile during the
       second year of the study. The HIV seropositive groups differed in the
       initial CD4 count, with a lower CD4 count (193 +/- 126 vs 437 +/- 142)
       and a higher F VIII consumption (63,000 +/- 17,000 vs 26,000 +/- 10,000)
       in the UP-F VIII group.(ABSTRACT TRUNCATED AT 250 WORDS)
 DE    Adolescence  Adult  Chromatography, Affinity  Chromatography, Ion
       Exchange  CD4 Lymphocyte Count  Disease Progression  Factor
       VIII/*ISOLATION & PURIF/THERAPEUTIC USE
       Hemophilia/COMPLICATIONS/IMMUNOLOGY/*THERAPY  Human  Hypersensitivity,
       Delayed/IMMUNOLOGY  HIV Infections/*COMPLICATIONS/IMMUNOLOGY
       Immunosorbent Techniques  Lymphocyte Transformation  Male  Prospective
       Studies  Support, Non-U.S. Gov't  CLINICAL TRIAL  CONTROLLED CLINICAL
       TRIAL  JOURNAL ARTICLE

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).